Ropanicant
- Generic Name
- Ropanicant
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
Phase 2
Not yet recruiting
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 195
- Registration Number
- NCT06836063
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 41
- Registration Number
- NCT06126497
- Locations
- 🇺🇸
Clinical Innovations, Inc, Bellflower, California, United States
🇺🇸Collaborative Neuroscience Research, LLC, Torrance, California, United States
🇺🇸NRC Research Institute, Orange, California, United States
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 28
- Registration Number
- NCT03551288
- Locations
- 🇺🇸
IQVIA Phase One Services, LLC, Kansas City, Kansas, United States
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2018-05-29
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 64
- Registration Number
- NCT03155503
- Locations
- 🇺🇸
QuintilesIMS Phase 1 Services, LLC, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath